Appointment of Joint Broker

RNS Number : 8892O

SkinBioTherapeutics PLC

01 February 2019

 

SkinBioTherapeutics plc

Appointment of Joint Broker

Manchester, UK - 1 February 2019 - SkinBioTherapeutics plc (AIM: SBTX - "SkinBioTherapeutics" or the "Company"), a life science company focused on skin health, announces that pursuant to the proposed merger between SP Angel Corporate Finance LLP ("SP Angel") and Northland Capital Partners Ltd, it has appointed SP Angel as its Joint Broker with immediate effect.

-ENDS-

For more information, please contact:

SkinBioTherapeutics plc Dr. Cath O'Neill, CEO Doug Quinn, CFO	Tel: [phone]
Cairn Financial Advisers LLP (Nominated Adviser) Tony Rawlinson / Sandy Jamieson / Richard Nash	Tel: [phone]
SP Angel Corporate Finance (Joint Broker) Vadim Alexandre / Abigail Wayne	Tel: [phone]
Turner Pope Investments (Joint Broker) Ben Turner / James Pope	Tel: [phone]
Instinctif Partners (Media Relations) Melanie Toyne-Sewell / Deborah Bell	Tel: [phone] [e-mail]

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O'Neill and Professor Andrew McBain.

SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. 

SkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix®. The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix (AIM: OPTI).

The Company joined AIM in April 2017 concurrent with raising £4.5 million from a placing of new ordinary shares.

The Company is based in Manchester, UK. For more information, visit www.skinbiotherapeutics.com.

 

END

 

 

APPBUGDDBDGBGCB